NewslettersHepatic Cell News FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma By Danielle Corrigan - September 16, 2022 0 GENFIT announced that the US FDA has granted orphan drug designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma. [GENFIT] Press Release